Elevated Adiponectin Serum Levels in Women with Systemic Autoimmune Diseases by Toussirot, Éric et al.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2010, Article ID 938408, 6 pages
doi:10.1155/2010/938408
Clinical Study
Elevated AdiponectinSerum Levelsin Womenwith
SystemicAutoimmune Diseases
´ EricToussirot,1,2,3 B´ eatrice Gaugler,2,4,5,6 MalikaBouhaddi,7,8 Nhu Uyen Nguyen,7,8
Philippe Saas,2,4,5,6 andGillesDumoulin7,8
1Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, 25030 Besanc ¸on Cedex, France
2University Hospital St Jacques, CIC Biotherapy-CBT 506, 25030 Besanc ¸on Cedex, France
3University of Franche Comt´ e, ´ Equipe d’Accueil 4266 “Agents Pathog` enes et Inﬂammation”, IFR133, 25000 Besanc ¸on, France
4INSERM UMR645, 1 Bd A Fleming, 25020 Besanc ¸on Cedex, France
5University of Franche-Comt´ e, UMR645, IFR133, 25020 Besanc ¸ o nC e d e x ,F r a n c e
6EFS Bourgogne Franche-Comt´ e, Plateforme de Biomonitoring, 25020 Besanc ¸on Cedex, France
7Department of Physiology, University Hospital Jean Minjoz, Bd Fleming, 25030 Besanc ¸on Cedex, France
8University of Franche Comt´ e, ´ Equipe d’Accueil EA 3920 “Physiopathologie Cardiovasculaire et Pr´ evention”,
IFR133, 25000 Besanc ¸on, France
Correspondence should be addressed to ´ Eric Toussirot, etoussirot@chu-besancon.fr
Received 20 April 2010; Revised 14 September 2010; Accepted 7 November 2010
Academic Editor: Oreste Gualillo
Copyright © 2010 ´ Eric Toussirot et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Adipose tissue produces a wide range of proteins that may inﬂuence the immune system. In this study, we assessed the serum
levels of leptin, adiponectin, and ghrelin, in association with the measurements of body composition, in 15 female patients with
various autoimmune diseases (systemic lupus erythematosus, primary Sj¨ ogren’s syndrome, sarcoidosis, mixed connective tissue
disease, vasculitis, CREST syndrome, and polymyositis) and in 15 healthy female controls. There were no statistically signiﬁcant
diﬀerences between the patients and controls with regard to serum leptin, serum ghrelin, global fat mass, adiposity, and fat mass
in the android or gynoid regions, whereas serum adiponectin levels were higher in patients than controls (16.3±1.6μg/mL versus
9.7 ± 0.6μg/mL; P = .01). As adiponectin is known to exhibit potent anti-inﬂammatory properties, a high adiponectinemia in
patients with systemic autoimmune disease may mitigate the inﬂammatory response. However, the precise consequences of these
elevated serum adiponectin levels on the metabolic syndrome development and atherosclerotic cardiovascular risk in this patient
population still needs to be determined.
1.Introduction
It is now well established that the adipose tissue, and more
precisely the white adipose tissue, is not only a storage organ
but plays an active role in that it can produce and release
various mediators that might play a role in the physiological
processes [1, 2]. Indeed, adipocytes produce speciﬁc pro-
teins or adipokines with a broad range of biological and
physiological activities related to glucose homeostasis, lipid
metabolism, appetite regulation, angiogenesis, hemostasis,
and reproduction as well as immunity. Adipose tissue is
composed of diﬀerent cellular types, of which the adipocytes
are the most abundant, but it also contains macrophages.
These macrophages can release various cytokines including
TNFαandIL-6[1–3].Inobesepatients,alow-gradesystemic
inﬂammation has been reported [1], as shown by increased
CRP and IL-6 levels compared to those observed in lean
subjects. This relationship between fat tissue and systemic
inﬂammation reﬂects the adipose tissue’s potential contri-
bution with regard to the inﬂammatory response, which
may be partly explained by the production of inﬂammatory
cytokines. In fact, macrophages from adipose tissue have
been shown to contribute to up to 30% of circulating IL-6,
indicating that adipose tissue is a signiﬁcant production site
of circulating proinﬂammatory cytokines [1, 2].
The main adipokines studied were leptin and
adiponectin. Leptin’s role on appetite regulation is well
documented, while adiponectin has been shown to be2 Mediators of Inﬂammation
involved in insulin sensitivity [1, 2]. The inﬂuence of these
adipokines on immunity and inﬂammation has been well
documented. In most inﬂammatory diseases, it is generally
accepted that leptin displays proinﬂammatory eﬀects, while
adiponectin is considered to primarily act as an anti-
inﬂammatory molecule. As an example, it has been reported
that leptin receptors are expressed on B and T-cells, and
that leptin may exert direct eﬀects on lymphocytes. Leptin
may stimulate T cell proliferation, promote a Th1 response,
inﬂuence T-cell activation, and activate macrophages and
monocytes, thereby enhancing their phagocytic activities.
In animal models, leptin deﬁciency has been associated
with immune suppression [1–4]. Adiponectin exerts a
variety of anti-inﬂammatory activities, interfering with
macrophage function by inhibiting phagocytosis, IL-6 or
TNFα production, reducing T-cell function, and promoting
the release of IL-10 and IL-1 receptor antagonist [1–3, 5].
Taken together, adipose tissue may inﬂuence or modulate
the inﬂammatory response.
Connective tissue diseases are systemic disorders which
may have a potential impact on several organs, and result
from the complex interaction between immunological, psy-
chological, environmental, hormonal, and genetic predis-
posing factors. Systemic lupus erythematosus (SLE) and
Sj¨ ogren’s syndrome (SS) are two prototypical autoimmune
diseases. This disease group also includes sarcoidosis, sys-
temic sclerosis, dermato/polymyositis, and systemic vas-
culitis. A common feature of all of these disorders is the
contributive and interactive role of autoantibodies, immune
complexes, and soluble mediators of cellular communication
(e.g., interleukins, chemokines, and growth factors) in tissue
damage.
Serum leptin and adiponectin have been previously
assessed in patients with SLE, giving conﬂicting results
[6–11]. This study aimed to assess circulating leptin and
adiponectin in patients with various systemic autoimmune
diseases in parallel with the evaluation of body composition,
and more especially fat mass. We also investigated serum
levels of ghrelin, a gastric peptide involved in both appetite
control and immunity regulation.
2. Patientsand Methods
2.1. Patients. Fifteen white consecutive outpatients with sys-
temic autoimmune disease who were seen in our department
were evaluated. This patient series included only women, as
it is well known that autoimmune diseases occur primarily
in women. The study group comprised patients with SLE
(N = 3), Sj¨ ogren’s syndrome (N = 7), sarcoidosis (N =
1), polymyositis (N = 1), CREST syndrome (N = 1),
mixed connective tissue disease (N = 1), or undiﬀerentiated
vasculitis (N = 1). All these patients met the speciﬁc
diagnostic criteria of the respective systemic autoimmune
diseases. Clinical assessment included demographic data
such as age, body mass index (BMI), disease duration,
and laboratory parameters of inﬂammation (erythrocyte
sedimentation rate [ESR], and CRP and IL-6 levels). To
be included in the study, no elevated acute phase reactants
were required. Excluded from the study were patients with
diabetes mellitus and other endocrine disorders (Cushing
syndrome or thyroid disease).The treatments administered
included nonsteroidal anti-inﬂammatory drugs and second-
line treatments (hydroxychloroquine, methotrexate). Corti-
costeroid dosage was required to be below or equal to 10mg
prednisone per day; cumulative and mean corticosteroid
dosages were also calculated. Among the patient group, 13
women were postmenopausal. As the patients suﬀered from
various autoimmune diseases, no speciﬁc scoring system for
clinical disease activity was used.
2.2. Controls. The control group included 15 healthy
white women with no history of inﬂammatory condition,
metabolic/endocrine disorders, or drug treatment (hospital
staﬀ). They were matched to the patients with regard to age
and BMI. The exclusion criteria were the same as those for
the patient group. Among the control group, 10 women were
postmenopausal.
The study protocol was approved by our institutional
ethics committee (Comit´ ed ’ ´ Ethique Clinique du CHU de
Besanc ¸on).
2.3. Measurements of Adipose Tissue. A total body scan
was performed using a Lunar iDXA densitometer (Lunar,
Madison, WI, USA). Measurements for body composition
were taken from the total body scan including fat mass
and lean mass. Total and regional body fat mass and lean
mass were also measured. Adiposity (% fat) was deﬁned
as the ratio between total fat tissue and total lean mass +
total fat tissue. Fat distribution was evaluated as the relative
proportion of fat tissue in the android (central) and the
gynoid (hip and thigh) regions. In our hands, the coeﬃcients
of variation for values for adiposity, fat mass, and lean mass
were 0.63%, 0.59%, and 0.45%, respectively, [12].
2.4. Adipokines, Ghrelin, and Insulin. After overnight fasting,
venous blood samples were taken at 8.00 a.m. from each
patient and control subject. The serum was stored at
20
◦C. Radioimmunoassay was used for measurements of
leptin (Mediagnost GmbH, Reutlingen, Germany) as well
as for total adiponectin (including high-molecular and
low-molecular weight complexes) and total ghrelin (Linco
Research, St Charles, MO, USA). Interassay coeﬃcients of
variation were 5.7% for leptin, 6.2% for adiponectin, and
7.9% for ghelin. The lowest level that could be detected by
each assay (sensitivity) was 0.5ng/mL for leptin, 1μg/mL
for adiponectin, and 93pg/mL for ghrelin. Serum leptin
concentrations were adjusted for fat mass. In addition,
fasting glycemia and insulin levels were determined (enzyme
immunoassay, ST AIA-PACK IRI, Tosoh corporation, Tokyo,
Japan). The homeostasis model assessment index for insulin
resistance (HOMA-IR), used as a marker of insulin resis-
tance, was calculated as previously described: fasting insulin
(μU/mL) × fasting glucose (mmol/L)/22.5 [13]. Detection of
IL-6 in the patients’ sera was performed by ELISA using IL-6
ELISA kit II BD OptEIA (BD Biosciences, Le Pont de Claix,
France).Fastingserumtotalcholesterolaswellaslow-densityMediators of Inﬂammation 3
Table 1: Demographics, body composition and distribution, serum adipokines and ghrelin levels in women with systemic autoimmune
disease, in patients with Sj¨ ogren syndrome and healthy women (results are given as mean ± SEM; P1: Man Whitney test between patients
with systemic autoimmune disease and healthy controls; P2:: Man Whitney test between patients with Sj¨ ogren’s syndrome and healthy
controls).
Systemic autoimmune diseases
whole series (N = 15)
Sj¨ ogren syndrome
(N=7)
Healthy controls
(N=1 5 )
P1 P2
Age (years) 57.7 ± 3.5 59.5 ± 3.7 54.5 ± 2.1 NS NS
Disease duration (years) 6.5 ± 1.4 4.7 ± 1.1 — ——
Clinical manifestations
Polyarthritis/ arthralgia: N = 14
Myalgia N = 2
Dermatological manifestations N = 2
Sicca syndrome N =7
Peripheral neuropathy N = 1
Pulmonary involvement N = 2
Raynaud syndrome N = 3
Renal disease N = 0
—— ——
BMI (kg/m2) 29.0 ± 1.9 32.03 ± 3.5 25.4 ± 1.1 NS NS
Corticosteroid dosage
(mg/day) 6.6 ± 1.3 5.7 ± 2.2 — ——
Cumulative corticosteroid
dose (mg) 11018 ± 4481 9192.8 ± 5349 — ——
ESR (mm/H) 16.3 ± 2.6 17.8 ± 4.6 14.5 ± 5.3 NS NS
CRP (mg/L) 6.5 ± 1.9 5 ± 25 . 7 ± 1.8 NS NS
IL-6 (pg/mL) 9.02 ±3.69 6.7 ± 3.2 0.02 ± 0.02 .025 .05
Glycemia (mmol/L) 4.8 ± 0.1 4.9 ± 0.2 4.6 ± 0.1 NS NS
Insulin (μIU/L) 10.3 ± 2.05 12.8 ± 3.9 8.6 ± 1.1 NS NS
HOMA-IR 2.14 ± 0.37 2.6 ± 0.6 1.49 ± 0.15 NS NS
Total cholesterol (g/L) 1.88 ± 0.1 1.9 ± 0.2 1.83 ± 0.1 NS NS
LDL cholesterol (g/L) 1.02 ± 0.1 1.05 ± 0.2 1.03 ± 0.1 NS NS
HDL cholesterol (g/L) 0.61 ± 0.04 0.7 ± 0.05 0.57 ± 0.04 NS NS
Leptin (ng/mL) 25.2 ± 5.6 31.1 ± 10.6 14.4 ± 3.4 NS NS
Leptin /fat mass
(ng/mL/Kg) 0.72 ± 0.1 0.7 ± 0.2 0.82 ± 0.1 NS NS
Adiponectin (μg/mL) 16.3 ± 1.6 17.8 ± 2.6 9.7 ± 0.6 .01 .04
Ghrelin (pg/mL) 1118 ± 127 1249. 1 ± 220.5 1012 ± 56 NS NS
Fat mass (g) 30140 ± 3411 33554.1 ± 5573.1 21518 ± 1862 NS NS
Lean mass (g) 40822 ± 1348 42475.7 ± 2128.5 47011 ± 1908 NS NS
Adiposity (%) 40.9 ± 2.3 42.8 ± 2.8 30.8 ± 1.8 NS NS
Fat in the android region
(g) 2681 ± 421 3099 ± 741.1 1951 ± 222 NS NS
Fat in the gynoid region (g) 5710 ± 541 6282.9 ± 794.2 3905 ± 340 NS NS
(ESR: erythrocyte sedimentation rate; BMI: body mass index; HOMA-IR: homeostasis model assessment index; NS: nonsigniﬁcant).
lipoprotein (LDL) cholesterol and high-density lipoprotein
(HDL) cholesterol were also evaluated.
2.5. Statistical Analysis. The data was analyzed using a com-
puted package for statistical analysis (Alsyd, SAS, Meylan,
France). All the measured variables were compared between
study patients and controls using the nonparametric Mann-
Whitney U-test . The relationship between the diﬀerent
variables (fat measurements, laboratory parameters of dis-
ease activity, and serum adipokines and ghrelin levels) were
analyzed using the Spearman’s r test. A P value inferior to
.05 was considered statistically signiﬁcant.
3. Results
The results were expressed as mean ± SEM, as shown in
Table 1. In the whole series, ﬁve patients and three healthy
controls were considered obese (BMI ≥ 30kg/m2). Overall,
11 patients were receiving prednisone at a mean dosage of
6.6 ± 1.3mg /day, while six were taking hydroxychloroquine
and seven methotrexate at study initiation. The cumulative
corticosteroiddosageforthesepatientswas11018 ±4481mg
prednisone equivalent.
As expected, patients and controls did not diﬀer regard-
ing age and BMI. There were no signiﬁcant between-group
diﬀerences in erythrocyte sedimentation rate and CRP levels,4 Mediators of Inﬂammation
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Figure 1: Serum adiponectin levels in 15 women suﬀering from
systemic autoimmune disease and in 15 healthy women. Each
value is represented by a blue diamond (patients with systemic
autoimmune disease) or a red square (control women). Means and
medians are represented by a grey bold line and black dotted line,
respectively. Mean and median values for each group are also given.
For statistical comparison, the Mann-Whitney U-test was used.
while IL-6 serum levels were markedly elevated in the patient
group (9.02 ± 3.7pg/mL versus 0.02 ± 0.02pg/mL; P =
.025). Between both groups, we found no signiﬁcant diﬀer-
ences regarding fat mass and lean mass as well as adiposity
and fat distribution in the android and gynoid regions (all
P>. 05). Adiponectin levels were higher in patients with
systemic autoimmune disease than in control subjects (16.3
± 1.6μg/mL versus 9.7 ± 0.6μg/mL; P = .01) (Figure 1).
Conversely, no statistically signiﬁcant diﬀerences between
patients and controls were observed for fasting glycemia,
insulin levels, HOMA-IR, total serum cholesterol, LDL and
HDL cholesterol, ghrelin, leptin, and leptin corrected by fat
mass (all P>. 05).
The relationships between fat mass, BMI, ghrelin,
adipokines, and disease activity parameters were then exam-
ined. As expected, we found a strong correlation between
circulating leptin levels and BMI, fat mass, or adiposity in
both patients (r = 0.92, r = 0.91 and r = 0.88, resp.; P< . 001
foralltests)andcontrolsubjects(r =0.93,r =0.91andr =.95,
resp.; P<. 001 for all tests). By contrast, and as previously
described [1, 2], there was no direct correlation between
adiponectin or ghrelin and fat mass measurements. Body
mass index, fat mass, and adiposity were slightly correlated
with CRP levels (r = 0.41, r = 0.49 and r = 0.45, resp.;
P ≤ .05 for all tests) but not with ESR or IL-6. Additionally,
the relationships between disease activity markers and serum
adiponectin levels were examined, and ESR and adiponectin
were found to be markedly and negatively correlated (r =
− 0.8, P = .003), whereas no relationship was observed
between adiponectin and CRP or IL-6 levels.
The serum levels of certain adipokines may be inﬂu-
enced by some treatments including corticosteroids and
methotrexate. For this reason, adiponectin serum levels
in the patient group were examined in relation with
corticosteroid or methotrexate use. Although adiponectin
serum levels were found to be higher in patients with or
without corticosteroids as compared to healthy controls, the
diﬀerence reached statistical signiﬁcance only for patients
who were not taking corticosteroids (healthy subjects (N
= 15) versus autoimmune disease patients without cor-
ticosteroids (N = 4): 10.64 ± 0.8μg/mL versus 19.9 ±
3.3μg/mL; P = .02), whereas only a trend towards a higher
adiponectinemiawasobservedforpatientswhowereactually
taking corticosteroids (healthy subjects (N = 15) versus
autoimmune disease patients with corticosteroids (N = 11):
10.64 ± 0.8μg/mL versus 15.1 ± 1.7μg/mL; P = .07). Similar
results were found for adiponectin when examining the use
of methotrexate (healthy subjects (N = 15) versus patients
without methotrexate (N = 8): 10.64 ± 0.8μg/mL versus
17.2 ± 2.4μg/mL; P = .04; healthy subjects (N = 15) versus
patients with methotexate (N = 7): 10.64 ± 0.8μg/mL versus
15.2 ± 2.1μg/mL; P = .07).
As our series included mainly subjects with Sj¨ ogren’s
syndrome (N = 7), results from this subgroup were analyzed
separately and compared to those obtained in healthy
subjects (Table 1). Similarly to the entire patient group,
higher IL-6 and adiponectin serum levels were noted in
patients with Sj¨ ogren’s syndrome as compared to healthy
controls (P = .05 and P = .04, resp.).
4. Discussion
In this study, we assessed the serum levels of adipokines such
leptin, adiponectin, and ghrelin, in association with body
compositionmeasurements,inwomenwithvarioussystemic
autoimmune diseases. The patient data was compared to
the results obtained in healthy subjects. The main outcome
of our study was that patients with systemic autoimmune
disease presented higher adiponectin levels than control
subjects, in contrast with the absence of diﬀerences observed
in serum leptin and ghrelin levels. Similarly, measurements
of body composition and distribution did not diﬀer between
both groups. Although patients with various autoimmune
diseases were included in our study, they were carefully
matched for age, sex, and BMI with the control subjects
in order to obtain a homogeneous comparison group. In
addition, all systemic autoimmune diseases included in the
study were characterized by common pathophysiological
processes induced by inﬂammatory mediators, that is,
cytokines such as TNFα or IL-6, and adipokines as well. As
our patient population was mainly comprised of patients
with primary Sj¨ ogren’s syndrome (N = 7), this prompted us
toanalyze,separately,theresultsforthispatientsubgroup.In
accordancewiththedatagatheredintheentirepatientgroup,
high adiponectinemiae (and IL-6 as well) was observed
in this subgroup. To our knowledge, no study so far has
evaluated adipokine levels in this speciﬁc patient population.
Our patients were receiving corticosteroid treatments at
a mean daily dose of 6.6 ± 1.3mg prednisone equivalent.Mediators of Inﬂammation 5
Corticosteroid treatment has been associated with the devel-
opment of adiposity involving predominantly the body’s
central or visceral regions, and contributing to increased
cardiovascular risk [14]. However, there was no diﬀerence
in android or visceral fat mass between the patients and
controls participating in our study. This may be explained
by the fact that our patients had received low-dose corticos-
teroid therapy. An interesting observation of our study was
that there was a signiﬁcant relationship between fat mass
measurements (total fat mass, adiposity) and laboratory
inﬂammation parameters such as CRP, reﬂecting the poten-
tial contribution of the adipose tissue to the inﬂammatory
response.
Our patients exhibited a signiﬁcant elevation in serum
adiponectin levels in line with previous works on SLE
patients [7, 8, 11], but no data was available so far on
adiponectin levels in patients suﬀering from other systemic
autoimmune diseases, notably primary Sj¨ ogren’s syndrome.
Thehighadiponectinemia foundinourpatientseriescannot
be explained by changes in fat mass or fat distribution. Our
patients were taking corticosteroids and/or methotrexate,
and these treatments have been associated with changes in
circulating adiponectin levels. However, high adiponectine-
mia was observed in both patients receiving or not receiving
corticosteroids or methotrexate, with statistically signiﬁcant
results observed only in the subgroup that was receiving
these drugs. While the eﬀects of corticosteroids on serum
adiponectin levels are controversial, [15, 16] adiponectin has
beenshowntoincreasemodestly(13%)duringmethotrexate
treatment in rheumatoid arthritis (RA) [17].
Previous studies have already reported high adiponectin
levels in systemic autoimmune diseases, even in patients
with a marked inﬂammatory response [8]. As proin-
ﬂammatory factors such as cytokines are known to sup-
press adiponectin production by adipocytes, this high
adiponectinemia in patients with inﬂammatory conditions
such systemic autoimmune diseases is paradoxical. Taking
intoaccountadiponectin’s anti-inﬂammatoryproperties, the
results of our study can be interpreted as a dampening
eﬀect of adiponectin on inﬂammation [5]. The negative
correlation that we noted between adiponectin and ESR
supportsthishypothesis,suggestingthatariseinadiponectin
levels could be a mechanism involved in the control of
inﬂammatory or immunological processes occurring in
these disease states. Alternatively, adiponectin has been
described as a potent proinﬂammatory mediator, as it
has been shown to stimulate the production of IL-6 and
prostaglandin E2 by synovial ﬁbroblasts in rheumatoid
arthritis patients, with serum adiponectin levels correlating
to the severity of rheumatoid arthritis evaluated by the
extent of joint destruction [18–20]. Thus, depending on
the model, adiponectin has been reported to display anti-
or proinﬂammatory activities. However, based on literature
data, adiponectin appears to display a predominantly anti-
inﬂammatory activity.
In addition to its pro/anti-inﬂammatory properties,
adiponectin has emerged as a key determinant of the
metabolic syndrome and may be considered as a protective
agent against cardiovascular risk [21]. Indeed, adiponectin
levelshavebeenreportedtobereducedinpatientspresenting
type 2 diabetes or metabolic syndrome, and low plasma
adiponectin concentrations closely correlate with obesity-
related diseases such as atherosclerotic cardiovascular dis-
eases [3, 21]. SLE has been shown to be associated with
insulin resistance, metabolic syndrome, and high cardiovas-
cular risk [7–9]. Unexpectedly, however, adiponectinemia
was found to be elevated in patients with SLE and insulin
resistance [7]. In our patients, we did not speciﬁcally
evaluate all of the components of the metabolic syndrome,
but high adiponectinemia did not inﬂuence insulin levels,
insulin resistance, or changes in lipid proﬁle. Whether high
adiponectinemia could have clinical consequences in these
patients, especially with regard to cardiovascular disease risk,
would require further longitudinal analysis.
Leptin serum levels have been evaluated in various
inﬂammatory conditions [2]. In RA, circulating and synovial
leptin levels were reported to be elevated compared to
those observed in healthy controls or osteoarthritis patients
[2]. In SLE, elevated serum leptin levels were observed in
most studies [6–9], while some authors reported normal or
decreased serum levels [10, 11]. On the basis of the results
observed in SLE patients, the authors speculated on the
possible inﬂuence of leptin on inﬂammation, certain clinical
manifestations, or weight changes during the course of the
disease [7]. However, no correlation was found between
leptin levels and clinical or biological disease activity indices
[8]. Our series included only three patients with SLE, and
these patients did not exhibit changes in circulating leptin.
Ghrelin was also evaluated in this study. This gastric
peptide has several physiologic functions involving GH
secretion, gastric function, control of blood pressure, and
adiposity as well as appetite stimulation and decreased fat
utilization. In addition to its role in the energetic balance,
ghrelin exhibits anti-inﬂammatory properties and there-
fore, its determination is relevant in studies investigating
adipokine levels in inﬂammatory disease states. Ghrelin has
beenshowntomodulatephagocytosis,whiledownregulating
innateimmunity[22,23].Ghrelinreceptorsareexpressedon
humanmonocytes,andthebindingofghrelintotheserecep-
tors inhibits the production of proinﬂammatory cytokines
such as IL-1, IL-6, or TNFα [24]. Ghrelin has previously
been evaluated in patients with RA [24]. While decreased
ghrelinserumlevelswerereportedinRApatients,circulating
ghrelin was increased in patients suﬀering from ankylosing
spondylitis, another inﬂammatory condition [25]. These
variations in ghrelin levels may inﬂuence the diﬀerent
inﬂammatory responses. However, our case series did not
exhibit signiﬁcant changes in serum ghrelin levels.
In conclusion, our study did not reveal any signiﬁcant
diﬀerences in serum leptin and ghrelin levels as well as
in body composition and distribution between systemic
autoimmune disease patients and healthy controls. Con-
trarily, patients with systemic autoimmune disease, partic-
ularly Sj¨ ogren’s syndrome, exhibited a marked increase in
circulating adiponectin. As adiponectin is thought to mainly
exert anti-inﬂammatory activities, high adiponectin levels
could inﬂuence or mitigate the inﬂammatory response or
immunopathological mechanisms involved in these disease6 Mediators of Inﬂammation
states. However, the precise consequences of this high
adiponectinemia on the metabolic syndrome development
and atherosclerotic cardiovascular risk in this patient pop-
ulation still need to be determined.
Conﬂict of Interests
The authors have no conﬂict of interests to declare.
References
[1] G. Fantuzzi, “Adipose tissue, adipokines, and inﬂammation,”
Journal of Allergy and Clinical Immunology, vol. 115, no. 5, pp.
911–920, 2005.
[2] E. Toussirot, G. Streit, and D. Wendling, “The contribution
of adipose tissue and adipokines to inﬂammation in joint
diseases,” Current Medicinal Chemistry, vol. 14, no. 10, pp.
1095–1100, 2007.
[3] F. Lago, C. Dieguez, J. G´ omez-Reino, and O. Gualillo,
“Adipokines as emerging mediators of immune response and
inﬂammation,” Nature Clinical Practice Rheumatology, vol. 3,
no. 12, pp. 716–724, 2007.
[4] M. Otero, R. Lago, R. Gomez et al., “Towards a pro-
inﬂammatory and immunomodulatory emerging role of
leptin,” Rheumatology, vol. 45, no. 8, pp. 944–950, 2006.
[5] G. Fantuzzi, “Adiponectin and inﬂammation: consensus and
controversy,” Journal of Allergy and Clinical Immunology, vol.
121, no. 2, pp. 326–330, 2008.
[6] A. Garcia-Gonzalez, L. Gonzalez-Lopez, I. C. Valera-Gonzalez
et al., “Serum leptin levels in women with systemic lupus
erythematosus,”RheumatologyInternational,v ol.22,no .4,pp .
138–141, 2002.
[7] K. E. Sada, Y. Yamasaki, M. Maruyama et al., “Altered
levels of adipocytokines in association with insulin resistance
in patients with systemic lupus erythematosus,” Journal of
Rheumatology, vol. 33, no. 8, pp. 1545–1552, 2006.
[8] C. P. Chung, A. G. Long, J. F. Solus et al., “Adipocytokines in
systemic lupus erythematosus: relationship to inﬂammation,
insulinresistanceandcoronaryatherosclerosis,”Lupus,vol.18,
no. 9, pp. 799–806, 2009.
[9] M. Vadacca, D. Margiotta, A. Rigon et al., “Adipokines and
systemic lupus erythematosus: relationship with metabolic
syndrome and cardiovascular disease risk factors,” Journal of
Rheumatology, vol. 36, no. 2, pp. 295–297, 2009.
[10] M. Wislowska, M. Rok, K. Stepien, and A. Kuklo-Kowalska,
“Serum leptin in systemic lupus erythematosus,” Rheumatol-
ogy International, vol. 28, no. 5, pp. 467–473, 2008.
[11] J. B. De Sanctis, M. Zabaleta, N. E. Bianco, J. V. Garmendia,
andL.Rivas,“Serumadipokinelevelsinpatientswithsystemic
lupus erythematosus,” Autoimmunity, vol. 42, no. 4, pp. 272–
274, 2009.
[12] E. Toussirot, C. Salmon, A. Penfornis, and D. Wendling,
“Precision evaluation of Lunar iDXA body composition
measurements,” Journal of Bone and Mineral Research, vol. 22,
supplement, p. S300, 2007.
[13] D.R.Matthews,J.P.Hosker,andA.S.Rudenski,“Homeostasis
model assessment: insulin resistance and β-cell function from
fasting plasma glucose and insulin concentrations in man,”
Diabetologia, vol. 28, no. 7, pp. 412–419, 1985.
[14] C. C. Mok, C. H. To, and K. M. Ma, “Changes in body
composition after glucocorticoid therapy in patients with
systemic lupus erythematosus,” Lupus, vol. 17, no. 11, pp.
1018–1022, 2008.
[15] K. C. Lewandowski, K. Szosland, and A. Lewinski, “Short-
term dexamethasone administration does not alter serum
adiponectin or resistin concentrations in overweight and
obese subjects despite an increase in insulin resistance,”
Clinical Endocrinology, vol. 65, no. 4, pp. 551–552, 2006.
[16] M. K. Vihinen, K. L. Kolho, O. A. J¨ anne, S. Andersson,
and T. Raivio, “Circulating adiponectin as a marker for
glucocorticoid-related side eﬀects in children and adolescents
with inﬂammatory bowel disease,” Journal of Pediatric Gas-
troenterology and Nutrition, vol. 48, no. 4, pp. 504–506, 2009.
[17] T. B. Laurberg, J. Frystyk, T. Ellingsen et al., “Plasma
adiponectin in patients with active, early, and chronic
rheumatoid arthritis who are steroid- and disease-modifying
antirheumatic drug-na¨ ıve compared with patients with
osteoarthritis and controls,” Journal of Rheumatology, vol. 36,
no. 9, pp. 1885–1891, 2009.
[18] N. Kusunoki, K. Kitahara, F. Kojima et al., “Adiponectin
stimulates prostaglandinEproductioninrheumatoidarthritis
synovial ﬁbroblasts,” Arthritis and Rheumatism, vol. 62, no. 6,
pp. 1641–1649, 2010.
[19] C. H. Tang, Y. C. Chiu, T. W. Tan, R. S. Yang, and W. M. Fu,
“Adiponectin enhances IL-6 production in human synovial
ﬁbroblast via an AdipoR1 receptor, AMPK, p38, and NF-κB
pathway,” Journal of Immunology, vol. 179, no. 8, pp. 5483–
5492, 2007.
[20] K. Ebina, A. Fukuhara, W. Ando et al., “Serum adiponectin
concentrations correlate with severity of rheumatoid arthritis
evaluated by extent of joint destruction,” Clinical Rheumatol-
ogy, vol. 28, no. 4, pp. 445–451, 2009.
[21] Y. Okamoto, S. Kihara, T. Funahashi, Y. Matsuzawa, and
P. Libby, “Adiponectin: a key adipocytokine in metabolic
syndrome,” Clinical Science, vol. 110, no. 3, pp. 267–278, 2006.
[22] N. Hattori, “Expression, regulation and biological actions of
growth hormone (GH) and ghrelin in the immune system,”
Growth Hormone and IGF Research, vol. 19, no. 3, pp. 187–
197, 2009.
[23] M. Delgado and D. Ganea, “Anti-inﬂammatory neuropep-
tides: a new class of endogenous immunoregulatory agents,”
Brain, Behavior, and Immunity, vol. 22, no. 8, pp. 1146–1151,
2008.
[24] M. Otero, R. Nogueiras, F. Lago, C. Dieguez, J. J. Gomez-
Reino, and O. Gualillo, “Chronic inﬂammation modulates
g h r e l i nl e v e l si nh u m a n sa n dr a t s , ”Rheumatology, vol. 43, no.
3, pp. 306–310, 2004.
[25] E. Toussirot, G. Streit, N. U. Nguyen et al., “Adipose tissue,
serum adipokines, and ghrelin in patients with ankylosing
spondylitis,” Metabolism: Clinical and Experimental, vol. 56,
no. 10, pp. 1383–1389, 2007.